JAZZ
JAZZ PHARMACEUTICALS PLC
JAZZ PHARMACEUTICALS PLC historical holders
total: 5
Tweedy, Browne Co All Funds (US) JAZZ PHARMACEUTICALS PLC transactions over time
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2026 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q1
Tweedy, Browne Co All Funds (US) has been an institutional investor in JAZZ PHARMACEUTICALS PLC (JAZZ) since 2026 Q1. According to 2026 Q1 report, Tweedy, Browne Co All Funds (US) holds 60,209 shares with a market value of roughly $11.38M representing 0.90% of their equity portfolio. The fund/company first acquired JAZZ in 2026 Q1, initially purchasing 60,209 shares.
Does Tweedy, Browne Co All Funds (US) still hold JAZZ?
Yes, Tweedy, Browne Co All Funds (US) continues to hold JAZZ PHARMACEUTICALS PLC (JAZZ). According to their 2026 Q1 report, they maintain a position of 60,209 shares valued at approximately $11.38M, representing 0.90% of their equity portfolio.
When did Tweedy, Browne Co All Funds (US) first invest in JAZZ?
Tweedy, Browne Co All Funds (US) first invested in JAZZ PHARMACEUTICALS PLC (JAZZ) in 2026 Q1 at the reported quarter-end price of $189.05 per share, acquiring 60,209 shares in their initial purchase.
What is Tweedy, Browne Co All Funds (US)'s average cost basis for JAZZ?
Based on historical transaction data, Tweedy, Browne Co All Funds (US)'s estimated cost basis for JAZZ PHARMACEUTICALS PLC (JAZZ) is approximately $189.05 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $189.05
JAZZ transactions history by Tweedy, Browne Co All Funds (US)
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.90%
|
60,209
|
$189.05
|
$11,382,511
|
new
|
+0.9%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.